Global Anticoagulation Market—Forecast till 2027

Global Anticoagulation Market—Forecast till 2027

$4450 – $6250

As per CRI’s report, global anticoagulation market is to reach a CAGR of 7.80% during the review period to surpass USD 31,696.59 million by 2027.

SKU: MRFR210205 Category: Tag:

Description

Anticoagulation Market Snapshot

As per CRI’s report, the global anticoagulation market is anticipated to register a healthy CAGR of 7.80% during the review period to surpass USD 31,696.59 million by 2027. Anticoagulants are ordinarily known as blood thinners, which are compound substances that decrease blood coagulation and blood thickening time.

Oral anticoagulants are accessible in different measurements structures, for example, pill or tablet structure and intravenous dose. Moreover, a portion of the anticoagulants is utilized in clinical hardware, for example, test tubes, blood bonding sacks, and dialysis gear. In addition, warfarin was initially supported as an anticoagulant.

The growth of the global anticoagulation market is attributed to the increasing prevalence of cardiovascular and coronary artery diseases, dependence on anticoagulants, and the growing geriatric population.

Many major market players and entrants have various attractive market opportunities due to the growing patient population supporting new product launches. However, stringent regulatory policies are expected to hinder the market growth during the review period.

Anticoagulation Market Segment Overview

The global anticoagulation market has been classified into Direct Oral Anticoagulants (DOACS), Disease Indication, Route of Administration (ROA), a distribution channel.

The direct oral anticoagulants segment has been further classified into Warfarin, another vitamin K, and Low Molecular Weight Heparin (LMWH).

Based on Disease Indication the global market is divided into Heart Attack, Stroke, Deep Vein Thrombosis/ Pulmonary Embolism DVT/PE, Mechanical Heart Valves (MHV).

Based on the Route of Administration (ROA) segment the global market has been segmented into Oral, injectable, and others.
By Distribution Channel the global market has been classified into Retail Pharmacy, Hospital Pharmacies, and Online Pharmacies.

Anticoagulation Market Regional Analysis

North America is likely to hold the greatest piece of the pie during the review time frame.

In North America, the anticoagulation market is driven by an expanding number of heart patients, rising mindfulness about constant and way of life infections, new item dispatches, and the presence of major players. Since medical care consumption is high in North America, anticoagulation is broadly used to lessen cluster arrangement, prompting the danger of coronary illness.

Asia-Pacific is expected to enroll the most elevated development rate during the figure time frame from 2020 to 2027. This is because of variables such as an expanding predominance of constant illness, enormous populace base, ascent in geriatric populace, rising discretionary cash flow, and increasing fabricating offices of vital participants.

Europe represented a market size of USD 5,205.37million in 2019 and is relied upon to show a CAGR of 7.26% during the gauge time frame. The market development is licensed to the ascent in research & development activities, expanded commonness of ongoing heart sicknesses, and an ascent sought after for cutting edge therapeutics.

Major Companies Covered

The key players of the global anticoagulation market are Pfizer Inc (US), Novartis AG (Switzerland), Sanofi (France), GlaxoSmithKline plc (UK), Daiichi Sankyo Company, Limited (Japan), Johnson & Johnson Services Inc (US), Boehringer Ingelheim International GmbH (Germany), Bristol-Myers Squibb Company (US), Hoffmann-La Roche Ltd (Switzerland), and Portola Pharmaceuticals, Inc (US).

COVID 19 Impacts on Anticoagulation Market

We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries.

Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

Global Leukemia Therapeutics Market 2029

Additional information

Publisher

Geography Covered

Date Published

Pages

Format

Table of Contents

LIST OF CONTENTS 1 EXECUTIVE SUMMARY 14 2 MARKET INTRODUCTION 15 2.1 DEFINITION 15 2.2 SCOPE OF THE STUDY 15 2.3 RESEARCH OBJECTIVE 15 2.4 MARKET STRUCTURE 15 2.5 ASSUMPTIONS & LIMITATIONS 16 3 RESEARCH METHODOLOGY 17 3.1 DATA MINING 17 3.2 SECONDARY RESEARCH 18 3.3 PRIMARY RESEARCH 18 3.4 BREAKDOWN OF PRIMARY RESPONDENTS 19 3.5 FORECASTING TECHNIQUES 20 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 21 3.6.1 BOTTOM-UP APPROACH 22 3.6.2 TOP-DOWN APPROACH 22 3.7 DATA TRIANGULATION 23 3.8 VALIDATION 23 4 MARKET DYNAMICS 24 4.1 OVERVIEW 24 4.2 DRIVERS 25 4.2.1 RISING INCIDENCE OF CARDIOVASCULAR AND CORONARY ARTERY DISEASES 25 4.2.2 GROWING AWARENESS, EXPENDITURE, AND DEPENDENCE ON ANTICOAGULANTS 25 4.3 RESTRAINTS 26 4.3.1 STRINGENT REGULATORY NORMS 26 4.4 OPPORTUNITIES 27 4.4.1 INCREASING PATIENT POPULATION AND PATENT EXPIRY TO SUPPORT NEW PRODUCT LAUNCH 27 5 MARKET FACTOR ANALYSIS 28 5.1 VALUE CHAIN ANALYSIS 28 5.1.1 R&D 29 5.1.2 MANUFACTURING 29 5.1.3 DISTRIBUTION AND SALES 29 5.1.4 POST-SALES MONITORING 29 5.2 PORTER'S FIVE FORCES MODEL 29 5.2.1 BARGAINING POWER OF SUPPLIERS 30 5.2.2 BARGAINING POWER OF BUYERS 30 5.2.3 THREAT OF NEW ENTRANTS 30 5.2.4 THREAT OF SUBSTITUTES 31 5.2.5 INTENSITY OF RIVALRY 31 5.2.6 US AND GLOBAL NUMBER OF PATIENTS ON ANTICOAGULANTS (2019), IN MILLION 31 5.3 IMPACT OF COVID-19 ON THE ANTICOAGULATION MARKET 32 5.3.1 OVERVIEW 32 5.3.2 IMPACT ON SUPPLY CHAIN 32 5.3.3 IMPACT ON DEMAND FOR ANTICOAGULATION DRUGS 32 5.3.4 EFFECT 0F ANTICOAGULATION ON COVID-19 PATIENTS 33 5.4 PATENT EXPIRATION OF ALL KEY DOACS 34 5.4.1 INTRODUCTION 34 6 GLOBAL ANTICOAGULATION MARKET, BY DRUG CLASS 35 6.1 OVERVIEW 35 6.2 DOACS 36 6.3 WARFARIN 38 6.4 OTHER VITAMIN K 39 6.5 LMWH 40 7 GLOBAL ANTICOAGULATION MARKET, BY DISEASE INDICATION 41 7.1 OVERVIEW 41 7.2 HEART ATTACK 42 7.3 STROKE 42 7.4 DVT/PE 43 7.5 MHV 43 7.6 OTHERS 44 8 GLOBAL ANTICOAGULATION MARKET, BY ROA 45 8.1 OVERVIEW 45 8.2 ORAL 46 8.3 INJECTABLE 46 8.4 OTHERS 47 9 GLOBAL ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL 48 9.1 OVERVIEW 48 9.2 RETAIL PHARMACY 49 9.3 HOSPITAL PHARMACIES 49 9.4 ONLINE PHARMACIES 50 10 GLOBAL ANTICOAGULATION MARKET, BY REGION 51 10.1 OVERVIEW 51 10.2 NORTH AMERICA 53 10.2.1 US 55 10.2.2 CANADA 57 10.3 EUROPE 59 10.3.1 GERMANY 61 10.3.2 UK 63 10.3.3 FRANCE 65 10.3.4 ITALY 67 10.3.5 SPAIN 69 10.3.6 REST OF EUROPE 71 10.4 ASIA-PACIFIC 73 10.5 REST OF THE WORLD 86 11 COMPETITIVE LANDSCAPE 94 11.1 OVERVIEW 94 11.2 COMPETITIVE BENCHMARKING 95 11.3 GLOBAL ANTICOAGULATION MARKET: COMPANY RANKING 96 11.4 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS 97 11.5 KEY DEVELOPMENTS & GROWTH STRATEGIES 97 11.5.1 NEW PRODUCT LAUNCHES 97 11.6 FINANCIAL MATRIX 98 12 COMPANY PROFILES 99 12.1 PFIZER, INC. 99 12.1.1 COMPANY OVERVIEW 99 12.1.2 FINANCIAL OVERVIEW 100 12.1.3 PRODUCTS/SERVICES OFFERED 100 12.1.4 KEY DEVELOPMENTS 100 12.1.5 SWOT ANALYSIS 101 12.1.6 KEY STRATEGIES 101 12.2 SANOFI 102 12.2.1 COMPANY OVERVIEW 102 12.2.2 FINANCIAL OVERVIEW 102 12.2.3 PRODUCTS/SERVICES OFFERED 103 12.2.4 KEY DEVELOPMENTS 103 12.2.5 SWOT ANALYSIS 103 12.2.6 KEY STRATEGIES 103 12.3 JOHNSON & JOHNSON SERVICES INC. 104 12.3.1 COMPANY OVERVIEW 104 12.3.2 FINANCIAL OVERVIEW 104 12.3.3 PRODUCTS/SERVICES OFFERED 105 12.3.4 KEY DEVELOPMENTS 105 12.3.5 SWOT ANALYSIS 105 12.3.6 KEY STRATEGIES 105 12.4 GLAXOSMITHKLINE PLC 106 12.4.1 COMPANY OVERVIEW 106 12.4.2 FINANCIAL OVERVIEW 106 12.4.3 PRODUCTS/SERVICES OFFERED 107 12.4.4 KEY DEVELOPMENTS 107 12.4.5 SWOT ANALYSIS 107 12.4.6 KEY STRATEGIES 107 12.5 DAIICHI SANKYO COMPANY, LIMITED 108 12.5.1 COMPANY OVERVIEWS 108 12.5.2 FINANCIAL OVERVIEW 108 12.5.3 PRODUCTS/SERVICES OFFERED 109 12.5.4 KEY DEVELOPMENTS 109 12.5.5 SWOT ANALYSIS 109 12.5.6 KEY STRATEGIES 110 12.6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 111 12.6.1 COMPANY OVERVIEW 111 12.6.2 FINANCIAL OVERVIEW 112 12.6.3 PRODUCTS/SERVICES OFFERED 112 12.6.4 KEY DEVELOPMENTS 113 12.6.5 SWOT ANALYSIS 113 12.6.6 KEY STRATEGIES 113 12.7 BRISTOL-MYERS SQUIBB COMPANY 114 12.7.1 COMPANY OVERVIEW 114 12.7.2 FINANCIAL OVERVIEW 114 12.7.3 PRODUCTS/SERVICES OFFERED 115 12.7.4 KEY DEVELOPMENTS 115 12.7.5 SWOT ANALYSIS 115 12.7.6 KEY STRATEGIES 115 12.8 PORTOLA PHARMACEUTICALS, INC 116 12.8.1 COMPANY OVERVIEW 116 12.8.2 FINANCIAL OVERVIEW 116 12.8.3 PRODUCTS/SERVICES OFFERED 117 12.8.4 KEY DEVELOPMENTS 117 12.8.5 SWOT ANALYSIS 118 12.8.6 KEY STRATEGIES 118 12.9 NOVARTIS AG 119 12.9.1 COMPANY OVERVIEW 119 12.9.2 FINANCIAL OVERVIEW 119 12.9.3 PRODUCTS/SERVICES OFFERED 120 12.9.4 KEY DEVELOPMENTS 120 12.9.5 SWOT ANALYSIS 120 12.9.6 KEY STRATEGIES 120 12.10 F. HOFFMANN-LA ROCHE LTD 121 12.10.1 COMPANY OVERVIEW 121 12.10.2 FINANCIAL OVERVIEW 122 12.10.3 PRODUCTS/SERVICES OFFERED 122 12.10.4 KEY DEVELOPMENTS 122 12.10.5 SWOT ANALYSIS 123 12.10.6 KEY STRATEGIES 123 13 APPENDIX 124 13.1 REFERENCES 124 13.2 RELATED REPORTS 124

Related products